先声药业(02096.HK)就SIM0500与AbbVie订立许可选择权协议

阿斯达克财经

01-13

先声药业(02096.HK) 公布，与AbbVie Inc.(ABBV.US) 附属订立许可选择权协议，据此，AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。

集团将从AbbVie收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。同时，将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)

AASTOCKS新闻

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503819885"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503819885\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503819885?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","is_english":false,"pubTime":"2025-01-13 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503819885","market":"fut","top_or_hot":-1,"title":"先声药业(02096.HK)就SIM0500与AbbVie订立许可选择权协议","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/02096\">先声药业</a>(02096.HK)<span> </span>公布，与AbbVie Inc.(ABBV.US)<span> </span><span> </span>附属订立许可选择权协议，据此，AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。<br/><span></span><br/>集团将从AbbVie收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。同时，将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>先声药业(02096.HK)就SIM0500与AbbVie订立许可选择权协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n先声药业(02096.HK)就SIM0500与AbbVie订立许可选择权协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 23:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410013/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>先声药业(02096.HK) 公布，与AbbVie Inc.(ABBV.US)  附属订立许可选择权协议，据此，AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。集团将从AbbVie收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。同时，将额外获得基于该产品在大中华区以外地区净销售额的分级...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410013/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1410013/latest-news/AAFN","article_id":"2503819885","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503819885","pubTimestamp":1736781840,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"先声药业(02096.HK) 公布，与AbbVie Inc.(ABBV.US)  附属订立许可选择权协议，据此，AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。集团将从AbbVie收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。同时，将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02096":"先声药业","BK1191":"制药","BK1583":"高瓴概念"},"translate_title":"Simcere Pharmaceuticals (02096. HK) enters into licensing option agreement with AbbVie for SIM0500","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"先声药业(02096.HK) 公布，与AbbVie Inc.(ABBV.US)  附属订立许可选择权协议，据此，AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。集团将从AbbVie收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。同时，将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}